Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Central Nervous System Therapeutic Market: By Disease Type, By Drug Class, By Distribution Channel, and Geography
Central Nervous System Therapeutic Market: By Disease Type, By Drug Class, By Distribution Channel, and Geography
Central Nervous System Therapeutics Market was valued at US$ 133.8 billion in 2023 and is expected to grow at a 7.41% CAGR from 2024 to 2030. The central nervous system is a vital part of the nervous system that consists of the brain and spinal cord. The CNS integrates the received information and, thereafter, coordinates and controls the activities of all parts of the body. The CNS disorders like autoimmune & inflammatory diseases, genetic disorders, neurodegenerative diseases, and others affect the structure and function of the brain and the spinal cord.
The increasing prevalence of mental illness and lifestyle associated with CNS disorders and a growing number of geriatric populations are expected to majorly drive the growth of the market over the forecast period. For instance, the rate of serious psychological distress among adolescents and young adults has been on the rise for the past few years, which is further expected to fuel the demand for CNS therapeutics across the globe. In addition, advancements in diagnostics, therapeutics, and drug discovery techniques are expected to further propel the growth of the central nervous system market over the forecast period.
Furthermore, the growing number of awareness programs about CNS disorders and their therapeutics by regulatory bodies in several developing countries across the globe is expected to have a positive impact on market growth. For instance, The World Health Organization and the American Association of Neurological Surgeons conduct various seminars to increase awareness about psychological disorders and their treatments. Moreover, the increasing demand for effective CNS therapy options encourages the market players and pharmaceutical companies to invest in research and development, thus creating growth opportunities in the CNS therapeutic market over the forecast period.
Study Period
2024-2030Base Year
2023CAGR
7.4%Largest Market
North AmericaFastest Growing Market
North America
The central nervous system therapeutic market is expected to grow over the forecasted period due to the increasing prevalence of CNS disorders such as neurodegenerative disease, autoimmune & inflammatory diseases, genetic disorders, cancer, and other disorders across the globe. the increasing burden of CNS disorders has resulted in huge government investment and support for research activities in the treatment of CNS disorders. For instance, in 2021 the United States Congress invested nearly USD 126 million in multiple sclerosis research. Furthermore, many ongoing clinical trials in the North America region are expected to further boost the growth of the Central Nervous System therapeutic market.
The central nervous system therapeutic market is segmented based on regions into North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. The North America central nervous system therapeutic market is likely to hold a significant revenue share, and in the forecasted years, it is predicted to increase rapidly due to the rapid growth and development of technologies in the healthcare sector in the US. In addition, the increasing prevalence of CNS disorders in geriatric patients in this region is anticipated to boost the market growth. Europe region is expected to have significant growth over the forecast period owing to the favorable reimbursement policies and the largest access to treatment by public healthcare providers in this region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 133.8 billion |
|
Market CAGR |
7.4% |
|
By Disease Type |
|
|
By Drug Class |
|
|
By Distribution Channel |
|
Download Free Sample Report
The global central nervous system therapeutics market size was valued at US$ 133.8 billion in 2023 and is projected to grow at a CAGR of 7.4% from 2024-2030.
The high cost of treatment and strict and prolonged approvals of drugs is expected to hinder the growth of the central nervous system therapeutic market.
The leading players in the global central nervous system therapeutics market are Pfizer. Biogen Inc., Johnson & Johnson Services Inc., Eli Lilly and Company Inc., Merck & Co. Inc., AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd., Shire Plc, Allergan Plc.
The North America central nervous system therapeutics market is likely to hold a significant revenue share and is expected to dominate the central nervous system therapeutic market.
| 1.Executive Summary |
| 2.Global Central Nervous System Therapeutics Market Introduction |
| 2.1.Global Central Nervous System Therapeutics Market - Taxonomy |
| 2.2.Global Central Nervous System Therapeutics Market - Definitions |
| 2.2.1.Disease Type |
| 2.2.2.Drug Class |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Central Nervous System Therapeutics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Central Nervous System Therapeutics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Central Nervous System Therapeutics Market By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Neurovascular Diseases |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Trauma |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Mental Health |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Degenerative Disease |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Infectious Diseases |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Cancer |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Others |
| 5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6.Global Central Nervous System Therapeutics Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Analgesics |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Antidepressants |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Anesthetics |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Anti-Parkinson Drugs |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Anti-Epileptics |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7.Global Central Nervous System Therapeutics Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacy |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacy |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacy |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Central Nervous System Therapeutics Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Central Nervous System Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Neurovascular Diseases |
| 9.1.2.Trauma |
| 9.1.3.Mental Health |
| 9.1.4.Degenerative Disease |
| 9.1.5.Infectious Diseases |
| 9.1.6.Cancer |
| 9.1.7.Others |
| 9.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Analgesics |
| 9.2.2.Antidepressants |
| 9.2.3.Anesthetics |
| 9.2.4.Anti-Parkinson Drugs |
| 9.2.5.Anti-Epileptics |
| 9.2.6.Others |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacy |
| 9.3.2.Retail Pharmacy |
| 9.3.3.Online Pharmacy |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Central Nervous System Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Neurovascular Diseases |
| 10.1.2.Trauma |
| 10.1.3.Mental Health |
| 10.1.4.Degenerative Disease |
| 10.1.5.Infectious Diseases |
| 10.1.6.Cancer |
| 10.1.7.Others |
| 10.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Analgesics |
| 10.2.2.Antidepressants |
| 10.2.3.Anesthetics |
| 10.2.4.Anti-Parkinson Drugs |
| 10.2.5.Anti-Epileptics |
| 10.2.6.Others |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacy |
| 10.3.2.Retail Pharmacy |
| 10.3.3.Online Pharmacy |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Central Nervous System Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Neurovascular Diseases |
| 11.1.2.Trauma |
| 11.1.3.Mental Health |
| 11.1.4.Degenerative Disease |
| 11.1.5.Infectious Diseases |
| 11.1.6.Cancer |
| 11.1.7.Others |
| 11.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Analgesics |
| 11.2.2.Antidepressants |
| 11.2.3.Anesthetics |
| 11.2.4.Anti-Parkinson Drugs |
| 11.2.5.Anti-Epileptics |
| 11.2.6.Others |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacy |
| 11.3.2.Retail Pharmacy |
| 11.3.3.Online Pharmacy |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Central Nervous System Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Neurovascular Diseases |
| 12.1.2.Trauma |
| 12.1.3.Mental Health |
| 12.1.4.Degenerative Disease |
| 12.1.5.Infectious Diseases |
| 12.1.6.Cancer |
| 12.1.7.Others |
| 12.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Analgesics |
| 12.2.2.Antidepressants |
| 12.2.3.Anesthetics |
| 12.2.4.Anti-Parkinson Drugs |
| 12.2.5.Anti-Epileptics |
| 12.2.6.Others |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacy |
| 12.3.2.Retail Pharmacy |
| 12.3.3.Online Pharmacy |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Central Nervous System Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Disease Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Neurovascular Diseases |
| 13.1.2.Trauma |
| 13.1.3.Mental Health |
| 13.1.4.Degenerative Disease |
| 13.1.5.Infectious Diseases |
| 13.1.6.Cancer |
| 13.1.7.Others |
| 13.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Analgesics |
| 13.2.2.Antidepressants |
| 13.2.3.Anesthetics |
| 13.2.4.Anti-Parkinson Drugs |
| 13.2.5.Anti-Epileptics |
| 13.2.6.Others |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacy |
| 13.3.2.Retail Pharmacy |
| 13.3.3.Online Pharmacy |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Pfizer |
| 14.2.2.Biogen Inc. |
| 14.2.3.Johnson & Johnson Services Inc. |
| 14.2.4.Eli Lilly and Company Inc. |
| 14.2.5.Merck & Co. Inc. |
| 14.2.6.AstraZeneca |
| 14.2.7.Novartis AG |
| 14.2.8.Teva Pharmaceutical Industries Ltd. |
| 14.2.9.Shire Plc |
| 14.2.10.Allergan Plc. |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.